Page last updated: 2024-09-22

11-hydroxy-delta(9)-tetrahydrocannabinol

Description

11-hydroxy-delta(9)-tetrahydrocannabinol: metabolite of marijuana; structure; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

11-hydroxy-Delta(9)-tetrahydrocannabinol : A phytocannabinoid that is Delta(9)-tetrahydrocannabinol in which the methyl group at C-11 has been hydroxylated . Major metabolite of Delta(9)-tetrahydrocannabinol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID644022
CHEMBL ID3229459
CHEBI ID77270
SCHEMBL ID20763968
MeSH IDM0041623

Synonyms (56)

Synonym
brn 4259929
11-hydroxy-delta(9)-tetrahydrocannabinol
6h-dibenzo(b,d)pyran-9-methanol, 6a,7,8,10a-tetrahydro-6,6-dimethyl-1-hydroxy-3-pentyl-, (6ar-trans)-
PDSP2_000207
7-hydroxy-delta(sup 1)tetrahydrocannabinol
11-hydroxy-delta9-tetrahydrocannabinol
(-)-7-hydroxy-delta1-tetrahydrocannabinol
(-)-11-hydroxy-delta9-thc
36557-05-8
11-hydroxy-delta9-thc
6h-dibenzo[b,d]pyran-9-methanol, 6a,7,8,10a-tetrahydro-1-hydroxy-6,6-dimethyl-3-pentyl-, (6ar-trans)-
7-hydroxy-delta1-tetrahydrocannabinol
11-hydroxy-delta(sup 9)tetrahydrocannabinol
11-hydroxytetrahydrocannabinol
11-oh-thc
(6ar,10ar)-9-(hydroxymethyl)-6,6-dimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
11-hydroxy-delta(9)-thc
7-hydroxy-delta(1)-tetrahydrocannabinol
11-hydroxy-delta(9)-tetrahydrocannabinol, (trans)-isomer
11-hydroxy-delta(9)-tetrahydrocannabinol, (6ar-trans)-isomer
bdbm84909
thc, 11-oh-delta 9
9vy04n5slb ,
unii-9vy04n5slb
(6ar,10ar)-6a,7,8,10a-tetrahydro-1-hydroxy-6,6-dimethyl-3-pentyl-6h-dibenzo[b,d]pyran-9-methanol
(-)-11-hydroxy-delta(9)-thc
chebi:77270 ,
EPITOPE ID:224558
(-)-11-hydroxy-delta(9)-tetrahydrocannabinol
6h-dibenzo(b,d)pyran-9-methanol, 6a,7,8,10a-tetrahydro-1-hydroxy-6,6-dimethyl-3-pentyl-, (6ar,10ar)-
11-hydroxy-.delta.9-thc
11-hydroxy-delta-9-tetrahydrocannabinol
11-hydroxy-.delta.9-tetrahydrocannabinol
(-)-11-hydroxy-.delta.9-thc
CHEMBL3229459
(6ar,10ar)-9-(hydroxymethyl)-6,6-dimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol
l-11-hydroxy-delta-9-thc
6h-dibenzo(b,d)pyran-9-methanol, 6a,7,8,10a-tetrahydro-6,6-dimethyl-1-hydroxy-3-pentyl-,(6ar-trans)-
7-hydroxy-.delta.1-tetrahydrocannabinol
9-(hydroxymethyl)-6,6-dimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol-, (6ar-trans)-
YCBKSSAWEUDACY-IAGOWNOFSA-N
11-hydroxy-.delta.-9-tetrahydrocannabinol
DTXSID50190061
(6ar,10ar)-rel-6a,7,8,10a-tetrahydro-1-hydroxy-6,6-dimethyl-3-pentyl-6h-dibenzo[b,d]pyran-9-methanol; trans-6a,7,8,10a-tetrahydro-1-hydroxy-6,6-dimethyl-3-pentyl-6h-dibenzo[b,d]pyran-9-methanol; (+/-)-11-hydroxy-?9-tetrahydrocannabinol; (+/-)-11-hydroxy-?
trans-11-hydroxy-delta9-thc ((6ars,10ars)-11-hydroxy-delta9-tetrahydrocannabinol) 0.1 mg/ml in methanol
34675-49-5
trans-11-hydroxy-delta9-thc ((6ars,10ars)-11-hydroxy-delta9-tetrahydrocannabinol) 1.0 mg/ml in methanol
(10ar)-9-(hydroxymethyl)-6,6-dimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol
Q63396108
SCHEMBL20763968
6h-dibenzo[b,d]pyran-9-methanol,6a,7,8,10a-tetrahydro-1-hydroxy-6,6-dimethyl-3-pentyl-,(6ar,10ar)-rel-
(-)-11-?9-tetrahydro cannabinol-9-methanol
(+/-)-11-hydroxy-delta9-thc (crm)
(+/-)-11-hydroxy-?9-thc (crm)
d,l-11-hydroxy-delta-9-thc, 0.1mg/ml in methanol
d,l-11-hydroxy-delta-9-thc, 1mg/ml in methanol

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
phytocannabinoidA class of cannabinoid which are C21 terpenophenolic compounds isolated primarily from Cannabis sativa.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1133175Molar volume, Vm of the compound at zero temperature1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Molar volume relationships and the specific inhibition of a synaptosomal enzyme by psychoactive cannabinoids.
AID1124427Analgesic activity in sc dosed mouse by hot-plate method1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Some 11-substituted tetrahydrocannabinols. Synthesis and comparison with the potent cannabinoid metabolites 11-hydroxytetrahydrocannabinols.
AID1124418Induction of overt behavior in dog at 0.10 mg/kg, iv1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Some 11-substituted tetrahydrocannabinols. Synthesis and comparison with the potent cannabinoid metabolites 11-hydroxytetrahydrocannabinols.
AID1124417Induction of overt behavior in dog at 0.05 mg/kg, iv1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Some 11-substituted tetrahydrocannabinols. Synthesis and comparison with the potent cannabinoid metabolites 11-hydroxytetrahydrocannabinols.
AID1133174Antihemolytic potency against hypotonic lysis-induced erythrocytes (unknown origin) assessed as stabilization1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Molar volume relationships and the specific inhibition of a synaptosomal enzyme by psychoactive cannabinoids.
AID1133173Inhibition of mouse brain synaptosomal Lysophosphatidylcholine acyltransferase using substrate [32P]lysophosphatidylcholine and oleoyl-CoA1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Molar volume relationships and the specific inhibition of a synaptosomal enzyme by psychoactive cannabinoids.
AID1124416Induction of overt behavior in dog at 0.01 mg/kg, iv1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Some 11-substituted tetrahydrocannabinols. Synthesis and comparison with the potent cannabinoid metabolites 11-hydroxytetrahydrocannabinols.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (77)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (19.48)18.7374
1990's12 (15.58)18.2507
2000's19 (24.68)29.6817
2010's28 (36.36)24.3611
2020's3 (3.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (13.48%)5.53%
Reviews2 (2.25%)6.00%
Case Studies2 (2.25%)4.05%
Observational0 (0.00%)0.25%
Other73 (82.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Safety/Toxicity (1)

ArticleYear
Intraocular pressure, ocular toxicity and neurotoxicity in response to 11-hydroxy-delta 9-tetrahydrocannabinol and 1-nantradol.
Journal of ocular pharmacology,Summer, Volume: 1, Issue: 2
1985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (1)

ArticleYear
Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV.
Forensic science international, Jul-16, Volume: 143, Issue: 2-3
2004
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (6)

ArticleYear
Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
European journal of drug metabolism and pharmacokinetics, Volume: 44, Issue: 5
2019
Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis.
Drug metabolism letters, Jun-01, Volume: 6, Issue: 2
2012
Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.
Clinical chemistry, Volume: 57, Issue: 10
2011
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Clinical chemistry, Volume: 57, Issue: 1
2011
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.
Clinical chemistry, Volume: 55, Issue: 12
2009
Molar volume relationships and the specific inhibition of a synaptosomal enzyme by psychoactive cannabinoids.
Journal of medicinal chemistry, Volume: 21, Issue: 12
1978
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (1)

ArticleYear
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Clinical chemistry, Volume: 57, Issue: 1
2011
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (8)

ArticleYear
Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
European journal of drug metabolism and pharmacokinetics, Volume: 44, Issue: 5
2019
Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration.
Clinical chemistry, Volume: 57, Issue: 11
2011
Antagonist-elicited cannabis withdrawal in humans.
Journal of clinical psychopharmacology, Volume: 31, Issue: 5
2011
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Clinical chemistry, Volume: 57, Issue: 1
2011
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.
Clinical chemistry, Volume: 55, Issue: 12
2009
Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
Therapeutic drug monitoring, Volume: 28, Issue: 4
2006
Effects of cannabinoids on progesterone release in cultures of rat luteal cells.
Life sciences, Nov-04, Volume: 37, Issue: 18
1985
Age-associated differences in cannabinoid-induced suppression of murine spleen, lymph node and thymus cell blastogenic responses.
Immunopharmacology, Volume: 14, Issue: 3
1987
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]